Literature DB >> 21259242

High sacrectomy for locally recurrent rectal cancer: Can long-term survival be achieved?

E J Dozois1, A Privitera, S D Holubar, J F Aldrete, F H Sim, P S Rose, M F Walsh, T C Bower, B C Leibovich, H Nelson, D W Larson.   

Abstract

BACKGROUND: Locally recurrent rectal cancer involving the upper sacrum is generally considered a contra-indication to curative surgery. The aim of this study was to determine if a survival benefit was seen in patients undergoing high sacrectomy.
METHODS: All patients with locally recurrent rectal cancer involving the sacrum above the 3rd sacral body between 1999 and 2007 were retrospectively reviewed. Kaplan-Meier survival analysis was performed.
RESULTS: Nine patients were identified with a median age of 63 years. The proximal extent of sacral resection was through S2 (n = 6), S1 (n = 2), and L5-S1 (n = 1). All patients had R0 negative-margin resection. Median operative time was 13.7 hr, and median operative blood transfusion was 3.7 L. Thirty-day mortality was nil. Postoperative complications requiring surgical intervention occurred in three patients. Local re-recurrence in the pelvis occurred in one patient. The overall median survival was 31 months (range, 2-39 months). Three patients still alive are free of disease after 40, 76, and 101 months, respectively. Ultimately, all deaths were due to metastatic disease.
CONCLUSIONS: High sacrectomy that achieves clear margins in patients with recurrent rectal cancer is safe and feasible. A majority will die of metastatic disease, but long-term survival may be possible in some patients.
Copyright © 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2010        PMID: 21259242     DOI: 10.1002/jso.21774

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  14 in total

Review 1.  Management of metastatic sacral tumours.

Authors:  Nasir A Quraishi; Kyriakos E Giannoulis; Kimberley L Edwards; Bronek M Boszczyk
Journal:  Eur Spine J       Date:  2012-06-23       Impact factor: 3.134

Review 2.  Surgery for Locally Advanced T4 Rectal Cancer: Strategies and Techniques.

Authors:  Ramzi M Helewa; Jason Park
Journal:  Clin Colon Rectal Surg       Date:  2016-06

3.  [Resection of recurrent rectal cancer].

Authors:  I Gockel; C Pommer; S Langer; B Jansen-Winkeln
Journal:  Chirurg       Date:  2018-08       Impact factor: 0.955

4.  Extended lateral pelvic sidewall excision (ELSiE): an approach to optimize complete resection rates in locally advanced or recurrent anorectal cancer involving the pelvic sidewall.

Authors:  I Shaikh; W Aston; G Hellawell; D Ross; S Littler; D Burling; M Marshall; J M A Northover; A Antoniou; J T Jenkins
Journal:  Tech Coloproctol       Date:  2014-11-08       Impact factor: 3.781

Review 5.  Pelvic exenteration for locally advanced and recurrent rectal cancer-how much more?

Authors:  Yee Chen Lau; Kilian G M Brown; Peter Lee
Journal:  J Gastrointest Oncol       Date:  2019-12

6.  Adenovirally delivered enzyme prodrug therapy with herpes simplex virus-thymidine kinase in composite tissue free flaps shows therapeutic efficacy in rat models of glioma.

Authors:  Rohit Seth; Aadil A Khan; Timothy D Pencavel; Michelle J Wilkinson; Joan N Kyula; Guy Simpson; Hardev Pandha; Alan Melcher; Richard Vile; Paul A Harris; Kevin J Harrington
Journal:  Plast Reconstr Surg       Date:  2015-02       Impact factor: 4.730

7.  Selection criteria for the radical treatment of locally advanced rectal cancer.

Authors:  Mansel Leigh Davies; Dean Harris; Mark Davies; Malcolm Lucas; Peter Drew; John Beynon
Journal:  Int J Surg Oncol       Date:  2011-10-13

8.  Surgical management of locally recurrent rectal cancer.

Authors:  Niamh M Hogan; Myles R Joyce
Journal:  Int J Surg Oncol       Date:  2012-06-03

9.  Pelvic exenteration: surgical approaches.

Authors:  Jin Kim
Journal:  J Korean Soc Coloproctol       Date:  2012-12-31

10.  Prognostic factors associated with locally recurrent rectal cancer following primary surgery (Review).

Authors:  Yantao Cai; Zhenyang Li; Xiaodong Gu; Yantian Fang; Jianbin Xiang; Zongyou Chen
Journal:  Oncol Lett       Date:  2013-10-23       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.